At DrHouse, every patient starting a GLP-1 gets a baseline panel: comprehensive metabolic panel, complete blood count, thyroid panel, lipid panel, hemoglobin A1C, urinalysis, and a pregnancy test for female patients
2024 Meta-Analysis Indicates That GLP-1RAs Reduce Adverse CV Events GLP1-RA therapy significantly reduces the risk of major adverse cardiovascular events (MACEs), all-cause mortality, CV mortality, stroke, risk for coronary revascularization, and composite adverse kidney outcomes in both sexes, regardless of a patient's history of cardiovascular disease, BMI or eGFR (Rivera et al, 2024)
New research shows GLP-1 drugs can help reduce pain and improve mobility, sometimes more than SGLT2 inhibitors
Improving Metabolic Health : Greater muscle mass helps improve control of blood sugar levels and reduce the risk of developing metabolic diseases
This is more than weight lossits a long-term investment in your health, vitality, and quality of life